Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelagliptin vs alogliptin on glycemic variation in type 2 diabetes
jRCT1080223195Phase 4
- Sponsor
- Takeda
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of trelagliptin and alogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoint: Glycemic variation under trelagliptin vs alogliptin.
02
Drugs
trelagliptinalogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080223195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223195.